They were showcasing Yseop Copilot, which they say is the world’s most secure content automation solution for regulated industries including pharma.
Nouri Chibane is vice president of sales at Yseop, and he was keen to explain more about the functions of Copilot, while his colleague, Camille Sauder, solutions engineer gave a demonstration.
He said: “More and more data are proliferated at the workplace, people are being asked to interact with it, and it's not really an efficient transaction.
“We call our product, Copilot, because it has been designed to sit alongside writers as an aid but not take over.”
The content automation tool, Chibane says, aims to fully assist life science companies in streamlining their automation needs. The platform uses pre-trained large language tools (LLMs) that give scientific writers the capability to highlight and enhance their productivity in a secure environment.
Writers involved in multiple clinical trials have massively reduced their writing time and consistency and reliability has greatly improved their report.
Chibane added with the software, they can help companies get to submission stage much quicker which means getting the therapies to patients faster.
He added: “We don't use the ChatGPT model, it's not secure with other things, but that same underlying technology is being used in our products, alongside other technologies and that increases the automation and coverage.
“That's what we do. It's automation alongside - and not instead of - the medical and scientific writers, and this was a big leap forward for us.”
“There's a productivity gain - we can now do with five people that used to take 10 which is what we found when we started out in the financial world and that's the case in this space. But there's a other small value dimensions, they're sciences which is getting the drug on market faster and that means a lot to the patients.”
Chibane said they had a lot of traffic throughout the DIA show and some difficult questions were asked.
He added: “They were asking about their use of ChatGPT and how this compares. I think the challenging thing for us is going to be what kind of an abstract they bring and then to help them understand how it can be used in a regulated environment. Some people are conservative in this industry and so on, so that could be a problem and then there's infrastructure and security concerns.
“I think people are pretty optimistic after they get used to the change. If they see the promise – and there’s just a lot that we need to bring to them through from what they used to.
Chibane said there is also a fear that people think it is going to take over their jobs, but I want to find a way to work with the end user and it is not that people are going to be marched out the door once technologies are deployed, that is not it at all.”
